Are cancer patients better off if they participate in clinical trials? A mixed methods study.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
08 May 2020
Historique:
received: 15 10 2019
accepted: 30 04 2020
entrez: 10 5 2020
pubmed: 10 5 2020
medline: 3 2 2021
Statut: epublish

Résumé

Research and cancer care are closely intertwined; however, it is not clear whether physicians and nurses believe that clinical trials offer the best treatment for patients and, if so, whether this belief is justified. The aim of this study was therefore: (i) to explore how physicians and nurses perceive the benefits of clinical trial participation compared with standard care and (ii) whether it is justified to claim that clinical trial participation improves outcomes for cancer patients. A mixed methods approach was used employing semi-structured interviews with 57 physicians and nurses in oncology and haematology and a literature review of the evidence for trial superiority, i.e. the idea that receiving treatment in a clinical trial leads to a better outcome compared with standard care. Inductive thematic analysis was used to examine the interview data. A literature review comprising nine articles was conducted according to a conceptual framework developed by Peppercorn et al. and evaluated recent evidence on trial superiority. Our findings show that many physicians and nurses make claims supporting trial superiority, however very little evidence is available in the literature comparing outcomes for trial participants and non-participants that supports their assertions. Despite the recent rapid development and use of targeted therapy and immunotherapy, we find no support for trial participation to provide better outcomes for cancer patients than standard care. Hence, our present results are in line with previous results from Peppercorn et al. A weaker version of the superiority claim is that even if a trial does not bring about a direct positive effect, it brings about indirect positive effects. However, as the value of such indirect effects is dependent on the individual's specific circumstances and preferences, their existence cannot establish the general claim that treatment in trials is superior. Belief in trial superiority is therefore unfounded. Hence, if such beliefs are communicated to patients in a trial recruitment context, it would provide misleading information. Instead emphasis should be on patients volunteering to give an altruistic contribution to the furthering of knowledge and to the potential benefit of future patients.

Sections du résumé

BACKGROUND BACKGROUND
Research and cancer care are closely intertwined; however, it is not clear whether physicians and nurses believe that clinical trials offer the best treatment for patients and, if so, whether this belief is justified. The aim of this study was therefore: (i) to explore how physicians and nurses perceive the benefits of clinical trial participation compared with standard care and (ii) whether it is justified to claim that clinical trial participation improves outcomes for cancer patients.
METHODS METHODS
A mixed methods approach was used employing semi-structured interviews with 57 physicians and nurses in oncology and haematology and a literature review of the evidence for trial superiority, i.e. the idea that receiving treatment in a clinical trial leads to a better outcome compared with standard care. Inductive thematic analysis was used to examine the interview data. A literature review comprising nine articles was conducted according to a conceptual framework developed by Peppercorn et al. and evaluated recent evidence on trial superiority.
RESULTS RESULTS
Our findings show that many physicians and nurses make claims supporting trial superiority, however very little evidence is available in the literature comparing outcomes for trial participants and non-participants that supports their assertions.
CONCLUSIONS CONCLUSIONS
Despite the recent rapid development and use of targeted therapy and immunotherapy, we find no support for trial participation to provide better outcomes for cancer patients than standard care. Hence, our present results are in line with previous results from Peppercorn et al. A weaker version of the superiority claim is that even if a trial does not bring about a direct positive effect, it brings about indirect positive effects. However, as the value of such indirect effects is dependent on the individual's specific circumstances and preferences, their existence cannot establish the general claim that treatment in trials is superior. Belief in trial superiority is therefore unfounded. Hence, if such beliefs are communicated to patients in a trial recruitment context, it would provide misleading information. Instead emphasis should be on patients volunteering to give an altruistic contribution to the furthering of knowledge and to the potential benefit of future patients.

Identifiants

pubmed: 32384883
doi: 10.1186/s12885-020-06916-z
pii: 10.1186/s12885-020-06916-z
pmc: PMC7206768
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

401

Références

ESMO Open. 2016 Jun 8;1(4):e000057
pubmed: 27843621
Breast. 2018 Apr;38:86-91
pubmed: 29287189
PLoS Med. 2016 Sep 20;13(9):e1002127
pubmed: 27649528
BJOG. 2018 Dec;125(13):1716
pubmed: 29916205
JAMA. 2003 Jan 22-29;289(4):454-65
pubmed: 12533125
Anticancer Res. 2016 Sep;36(9):4947-50
pubmed: 27630353
Oncology. 2016;91(4):185-193
pubmed: 27449344
Biol Blood Marrow Transplant. 2015 Oct;21(10):1815-22
pubmed: 26071866
J Clin Nurs. 2019 Jul;28(13-14):2443-2461
pubmed: 30673153
Lancet. 2004 Jan 24;363(9405):263-70
pubmed: 14751698
Nat Med. 2018 Jun;24(6):724-730
pubmed: 29867227
Ann Oncol. 2015 Aug;26(8):1547-73
pubmed: 26026162
J Natl Cancer Inst. 2002 Dec 18;94(24):1847-53
pubmed: 12488478
JAMA Oncol. 2016 Jan;2(1):139-41
pubmed: 26512913
Oncology. 2017;93(3):164-176
pubmed: 28601879
J Clin Neurosci. 2013 Jun;20(6):783-9
pubmed: 23639619
J Clin Epidemiol. 2019 Apr;108:95-101
pubmed: 30553831
J Clin Oncol. 2012 Dec 10;30(35):4396-400
pubmed: 23091107
J Med Libr Assoc. 2019 Jan;107(1):16-29
pubmed: 30598645
Acta Oncol. 2015 Feb;54(2):145-7
pubmed: 25608927
Breast Cancer Res Treat. 2016 Sep;159(2):273-81
pubmed: 27530453
Scand J Urol. 2016 Aug;50(4):286-91
pubmed: 27109827
Eur J Cancer Care (Engl). 2018 Nov;27(6):e12937
pubmed: 30277632
Biochem Med (Zagreb). 2017 Oct 15;27(3):030201
pubmed: 29180912
Ann Oncol. 2013 Dec;24(12):2972-7
pubmed: 24126362
Eur J Cancer Care (Engl). 2018 Nov;27(6):e12908
pubmed: 30179287
Am J Manag Care. 2005 Jul;11(7):413-21
pubmed: 16044978
Trials. 2015 Dec 08;16:558
pubmed: 26646545
J Empir Res Hum Res Ethics. 2018 Dec;13(5):475-485
pubmed: 29998780
Support Care Cancer. 2013 Nov;21(11):3137-42
pubmed: 23864288
PLoS One. 2019 Apr 12;14(4):e0215052
pubmed: 30978228
J Clin Oncol. 2008 Nov 1;26(31):5020-1
pubmed: 18794538
Eur J Cancer. 2011 Jul;47(10):1490-7
pubmed: 21454072
Acad Med. 2014 Sep;89(9):1245-51
pubmed: 24979285
BMJ. 2010 Sep 17;341:c4587
pubmed: 20851841
Trials. 2018 Sep 29;19(1):528
pubmed: 30268150
Trials. 2016 Jan 09;17:17
pubmed: 26745891
BMJ Evid Based Med. 2018 Jun;23(3):84-86
pubmed: 29650725
Health Technol Assess. 2010 Feb;14(8):iii, ix-xi, 1-193
pubmed: 20181324

Auteurs

Zandra Engelbak Nielsen (Z)

Department of Oncology, Copenhagen University Hospital, Copenhagen, Section 5073, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.

Stefan Eriksson (S)

Centre for Research Ethics & Bioethics, Uppsala University, Box 564, 751 22, Uppsala, Sweden.

Laurine Bente Schram Harsløf (LB)

Department of Oncology, Copenhagen University Hospital, Copenhagen, Section 5073, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.

Suzanne Petri (S)

Department of Oncology, Copenhagen University Hospital, Copenhagen, Section 5073, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.

Gert Helgesson (G)

Stockholm Centre for Healthcare Ethics (CHE), LIME, Karolinska Institutet, 171 77, Stockholm, Sweden.

Margrete Mangset (M)

Department of Geriatric Medicine, Oslo University Hospital, Kirkeveien 166, Bygg 20, 0450, Oslo, Norway.

Tove E Godskesen (TE)

Centre for Research Ethics & Bioethics, Uppsala University, Box 564, 751 22, Uppsala, Sweden. tove.godskesen@crb.uu.se.
Department of Health Care Sciences, Ersta Sköndal Bräcke University College, Box 11189, 100 61, Stockholm, Sweden. tove.godskesen@crb.uu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH